OBJECTIVE Despite the known negative physiological impact of repeated mild head trauma events, their multiplicative impact on long-term seizure risk remains unclear. The objective of this study was to evaluate how multiple mild traumatic brain injuries (mTBIs) impact long-term seizure risk by testing 3 distinct machine learning approaches. Baseline and injury-specific characteristics were incorporated to enhance prognostication of individual seizure risk. METHODS Children with at least 1 mTBI event without prior evidence of seizure or antiepileptic drug treatment, from 2003 to 2021, were identified from a nationally sourced administrative claims database. The primary outcome of interest was a seizure event after mTBI, defined by qualifying principal diagnosis codes. Time-varying multivariable Cox regression was used to assess the impact of repeated mTBI. RESULTS A total of 156,118 children (mean age 11.7 ± 4.7 years) were included, with a median follow-up duration of 22.6 months (IQR 9.2–45.4 months). Among patients who experienced seizure after mTBI, the median time to seizure was 306 days. Seizures among those with radiographic findings and/or loss of consciousness occurred earlier (median time to seizure 112.5 days [imaging findings only, IQR 5–526.25 days], 80 days [loss of consciousness only, IQR 7–652 days], 22 days [both, IQR 5–192 days]). Both mTBI without and with short-term loss of consciousness resulted in increasing seizure risk with repeated trauma (HR 1.196, 95% CI 1.082–1.322; HR 2.025, 95% CI 1.828–2.244; respectively). The random survival forest approach achieved fixed-time areas under the receiver operating characteristic curve of 0.780 and 0.777 at 30 and 90 days after mTBI, and children predicted at high risk by the final model experienced a significantly higher burden of early seizure after mTBI (46.7% within the first 30 days vs 17.7% and 19.9% of children at low and medium risk). A simplified model using the top 12 contributing features achieved 95% of the full model’s performance in the validation set. CONCLUSIONS A novel machine learning model was developed and validated for personalized prediction of long-term seizure risk following multiple mTBIs. Model performance remained robust with a limited feature set, suggesting the feasibility of real-time incorporation into clinical workflows for individualized prognostication following each repeat mTBI event. In children predicted to be at high risk, early intervention should be considered.
SP35. Effect of Brachial Plexus Birth Injury Model on Bone Growth
Objectives: Systemic beta-blockers are highly effective for the management of infantile hemangiomas (IH), but little is known about infants who do not adequately respond. We aimed to describe the characteristics and outcomes of suboptimal responders to standard-dose systemic beta-blockers in infants with IH. Methods: This is a multicenter retrospective cohort study to evaluate demographics, IH lesion characteristics, and treatment specifics of infants with IH with suboptimal response to baseline standard-dose propranolol treatment. Clinical response was used to assess the outcome after a therapeutic change. Results: Twenty-five infants were included in this study. Seven (28%) had segmental IH, 16 (64%) focal, and 2 (8%) indeterminate. The IHs were located on the head and neck in 21 (84%) infants, with 24 (96%) having a deep or combined component. Therapy changes after standard-dose propranolol treatment failure, most commonly by escalating propranolol dose to ≥2.5 mg/kg/d (59%) or surgical interventions (29%), were associated with good therapeutic effects. Conclusion: Among suboptimal responders to standard-dose systemic propranolol, IHs with a deep or combined component and located on the head and neck were the most common. This retrospective study was largely descriptive in nature with additional exploratory analyses. However, it is still encouraging that for patients with a suboptimal clinical response, higher propranolol doses of ≥2.5–3 mg/kg/d or second-line treatments with surgical interventions or systemic steroids can be considered as potentially safe and effective alternatives. Level of evidence: Level 4 (case series).
Delayed Diagnosis in X-Linked Agammaglobulinemia and Its Relationship to the Occurrence of Mutations in the Bruton Tyrosine Kinase Catalytic Domain
Background Bruton tyrosine kinase (BTK) is a protein-coding gene crucial for B cell development. It is found on Xq21.3-Xq22 of the long arm of the X chromosome and belongs to the Tec family of cytoplasmic protein tyrosine kinases consisting of 5 structural domains: PH, TH, Src3, Src2, and TK. Pathogenic variants in the BTK gene can fully or partially block B cell development. BTK has been linked to various antibody deficiencies beyond agammaglobulinemia, including CVID. In hypomorphic BTK variants, there are detectable B cells in the periphery that may result in variable levels of serum immunoglobulins and clinical phenotype. Objective Investigate the impact of a missense pathogenic hypomorphic BTK variant (p.Arg525Gln) observed in a large kindred. Results We plan to assess by flow cytometry BTK protein expression in specific B cell subsets in hypomorphic XLA patients in this kindred. The flow cytometry revealed a uniformly reduced BTK expression in B cells (B cells evaluation is limited by low cell counts). BTK expression was decreased with an unexpected bimodal distribution in monocytes. Since both patients were male, XXY syndrome was initially considered but deemed less likely. The unexpected monocyte expression pattern in the current patient suggests possible somatic mosaicism or other genetic factors, or the two peaks are related to BTK protein degradation, and this may differ in specific cellular compartments or change with age, warranting further investigation. Conclusions This highlights the challenges of diagnosing hypomorphic XLA, especially in patients with detectable B cell counts and atypical BTK expression. Flow cytometric analysis of two patients with BTK mutations identified bimodal mosaic patterns of BTK expression in monocytes. This bimodal expression pattern may reflect cellular mosaicism like in mothers who are obligate carriers of XLA. BTK biology with hypomorphic variants remains incompletely understood, particularly how these variants affect B cell development and result in milder antibody deficiency phenotypes, warranting further investigation. This emphasizes the importance of genetic screening in kindreds with XLA and the need for increased awareness of partial XLA among healthcare providers to ensure timely diagnosis and treatment.